Dendritic Immunotherapy Improvement for an Optimal Control Murine Model

Therapeutic protocols in immunotherapy are usually proposed following the intuition and experience of the therapist. In order to deduce such protocols mathematical modeling, optimal control and simulations are used instead of the therapist's experience. Clinical efficacy of dendritic cell (DC) vaccines to cancer treatment is still unclear, since dendritic cells face several obstacles in the host environment, such as immunosuppression and poor transference to the lymph nodes reducing the vaccine effect. In view of that, we have created a mathematical murine model to measure the effects of dendritic cell injections admitting such obstacles. In addition, the model considers a therapy given by bolus injections of small duration as opposed to a continual dose. Doses timing defines the therapeutic protocols, which in turn are improved to minimize the tumor mass by an optimal control algorithm. We intend to supplement therapist's experience and intuition in the protocol's implementation. Experimental results made on mice infected with melanoma with and without therapy agree with the model. It is shown that the dendritic cells' percentage that manages to reach the lymph nodes has a crucial impact on the therapy outcome. This suggests that efforts in finding better methods to deliver DC vaccines should be pursued.

[1]  Benedetto Piccoli,et al.  Optimal Control in a Model of Dendritic Cell Transfection Cancer Immunotherapy , 2006, 2004 43rd IEEE Conference on Decision and Control (CDC) (IEEE Cat. No.04CH37601).

[2]  Urszula Ledzewicz,et al.  Optimal Control for Mathematical Models of Cancer Therapies: An Application of Geometric Methods , 2015 .

[3]  N. Bhardwaj,et al.  Dendritic cell immunotherapy , 2013, Annals of the New York Academy of Sciences.

[4]  Jasbir S. Arora,et al.  Introduction to Optimum Design , 1988 .

[5]  J. C. Chimal-Eguía,et al.  Enhancing dendritic cell immunotherapy for melanoma using a simple mathematical model , 2015, Theoretical Biology and Medical Modelling.

[6]  Katia Jarquín-Yáñez,et al.  GK-1 Improves the Immune Response Induced by Bone Marrow Dendritic Cells Loaded with MAGE-AX in Mice with Melanoma , 2014, Journal of immunology research.

[7]  Nina Bhardwaj,et al.  CD8+ T Cell Priming by Dendritic Cell Vaccines Requires Antigen Transfer to Endogenous Antigen Presenting Cells , 2010, PloS one.

[8]  W. Oyen,et al.  Limited Amounts of Dendritic Cells Migrate into the T-Cell Area of Lymph Nodes but Have High Immune Activating Potential in Melanoma Patients , 2009, Clinical Cancer Research.

[9]  L. G. de Pillis,et al.  OPTIMAL CONTROL OF MIXED IMMUNOTHERAPY AND CHEMOTHERAPY OF TUMORS , 2008 .

[10]  Benedetto Piccoli,et al.  Determination of the optimal therapeutic protocols in cancer immunotherapy. , 2007, Mathematical biosciences.

[11]  S. Rosenberg,et al.  Cancer immunotherapy: moving beyond current vaccines , 2004, Nature Medicine.

[12]  Raluca Eftimie,et al.  Mathematical Models for Immunology: Current State of the Art and Future Research Directions , 2016, Bulletin of mathematical biology.

[13]  Y. Kogan,et al.  Improving T-cell Immunotherapy for Melanoma Through a Mathematically Motivated Strategy: Efficacy in Numbers? , 2012, Journal of immunotherapy.

[14]  A. Radunskaya,et al.  A Model of Dendritic Cell Therapy for Melanoma , 2013, Front. Oncol..